Free Trial

iBio (IBIO) Competitors

iBio logo
$0.57 -0.01 (-2.25%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 +0.00 (+0.51%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IBIO vs. ACRV, GRCE, EGRX, COEP, LVTX, SLGL, STTK, OVID, HYPD, and ENLV

Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Acrivon Therapeutics (ACRV), Grace Therapeutics (GRCE), Eagle Pharmaceuticals (EGRX), Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.

iBio vs. Its Competitors

Acrivon Therapeutics (NASDAQ:ACRV) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Acrivon Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Acrivon Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 0 mentions for iBio. Acrivon Therapeutics' average media sentiment score of 0.62 beat iBio's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Acrivon Therapeutics Positive
iBio Neutral

Acrivon Therapeutics currently has a consensus target price of $17.71, suggesting a potential upside of 1,317.14%. iBio has a consensus target price of $5.00, suggesting a potential upside of 772.45%. Given Acrivon Therapeutics' higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than iBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.00
iBio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Acrivon Therapeutics' return on equity of -44.66% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -44.66% -40.94%
iBio N/A -73.15%-45.51%

iBio has higher revenue and earnings than Acrivon Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$80.56M-$2.22-0.56
iBio$375K25.25-$24.91MN/AN/A

Summary

Acrivon Therapeutics beats iBio on 10 of the 12 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBIO vs. The Competition

MetriciBioPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$9.47M$830.25M$5.50B$20.66B
Dividend YieldN/A4.84%4.64%3.66%
P/E RatioN/A1.1730.3928.37
Price / Sales25.2525.76447.5260.19
Price / CashN/A19.5637.7222.93
Price / Book0.416.538.305.38
Net Income-$24.91M-$4.39M$3.26B$994.60M
7 Day Performance-7.99%1.22%0.91%1.50%
1 Month Performance-29.65%-0.20%3.66%0.49%
1 Year Performance-63.73%22.91%46.29%18.07%

iBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBIO
iBio
1.1741 of 5 stars
$0.57
-2.3%
$5.00
+772.4%
-62.4%$9.47M$375K0.00100
ACRV
Acrivon Therapeutics
3.2752 of 5 stars
$1.33
+5.6%
$17.71
+1,231.9%
-84.0%$41.70MN/A-0.6058News Coverage
GRCE
Grace Therapeutics
2.8195 of 5 stars
$3.00
+4.5%
$12.00
+300.0%
N/A$41.49MN/A-3.37N/ANews Coverage
Earnings Report
Gap Up
High Trading Volume
EGRX
Eagle Pharmaceuticals
N/A$3.19
-13.6%
N/A-21.8%$41.43M$257.55M0.00100Gap Down
COEP
Coeptis Therapeutics
0.6139 of 5 stars
$11.55
+7.7%
N/A+173.8%$40.54MN/A-1.992
LVTX
LAVA Therapeutics
1.8523 of 5 stars
$1.47
+3.5%
$3.17
+115.4%
-14.1%$38.67M$4.99M-1.4160Upcoming Earnings
High Trading Volume
SLGL
Sol-Gel Technologies
2.9294 of 5 stars
$13.42
+3.2%
$40.00
+198.1%
+337.0%$37.44M$11.54M-2.8650Upcoming Earnings
Gap Up
STTK
Shattuck Labs
3.4927 of 5 stars
$0.74
+1.5%
$7.50
+909.8%
-75.7%$35.58M$4.61M-0.53100Upcoming Earnings
OVID
Ovid Therapeutics
4.6387 of 5 stars
$0.50
-0.7%
$3.13
+529.4%
-38.0%$35.31M$570K-1.4260News Coverage
Gap Up
HYPD
Hyperion DeFi
0.2871 of 5 stars
$6.29
-11.2%
$2.00
-68.2%
-88.6%$35.24M$67.06K-0.1140Gap Up
ENLV
Enlivex Therapeutics
2.744 of 5 stars
$1.48
+2.1%
$10.00
+575.7%
+17.6%$35.00MN/A-2.2470Gap Up
High Trading Volume

Related Companies and Tools


This page (NYSE:IBIO) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners